Scarica l'app Stockscreener
43.83
0.00%
0.00
Dopo l'orario di chiusura:
43.78
-0.05
-0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$43.83
Aprire:
$43.93
Volume 24 ore:
10.10M
Relative Volume:
0.73
Capitalizzazione di mercato:
$89.21B
Reddito:
$47.70B
Utile/perdita netta:
$5.07B
Rapporto P/E:
17.68
EPS:
2.4784
Flusso di cassa netto:
$14.58B
1 W Prestazione:
+0.46%
1M Prestazione:
-0.75%
6M Prestazione:
-9.98%
1 anno Prestazione:
-17.18%
Intervallo 1D:
$43.58
$43.94
Intervallo di 1 settimana:
$43.34
$45.23
Portata 52W:
$42.96
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Confronta BMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
43.83 | 89.21B | 47.70B | 5.07B | 14.58B | 2.4784 |
|
LLY
Lilly Eli Co
|
825.45 | 736.03B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.40 | 463.72B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.99 | 403.22B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
130.36 | 254.84B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.49 | 217.76B | 63.43B | 16.42B | 14.72B | 6.4861 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Iniziato | Piper Sandler | Overweight |
| 2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
| 2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-07-10 | Iniziato | SVB Securities | Market Perform |
| 2023-06-28 | Iniziato | Daiwa Securities | Outperform |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Underweight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-01 | Downgrade | Argus | Buy → Hold |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Aggiornamento | Truist | Hold → Buy |
| 2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-07-28 | Iniziato | Raymond James | Outperform |
| 2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-06 | Ripresa | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | Argus | Hold → Buy |
| 2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-05-20 | Downgrade | Argus | Buy → Hold |
| 2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Ripresa | JP Morgan | Overweight |
| 2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
| 2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
How Bristol Myers Squibb Company Celegne Contingent stock trades under stagflationJuly 2025 Catalysts & Fast Exit Strategy with Risk Control - newser.com
Bristol Myers Squibb reports positive early results from CAR T therapy trial - Investing.com
Bristol Myers Squibb (NYSE: BMY) shares Phase 1 CD19 CAR T in 71 autoimmune patients - Stock Titan
BRISTOL-MYERS SQUIBB CO USD2 CNV CUM PFD USD1 (BMYMP.US) is scheduled to release its earnings report before the market opens on October 30. - 富途牛牛
Applying chart zones and confluence areas to Bristol Myers Squibb CompanyJuly 2025 Highlights & Safe Swing Trade Setup Alerts - newser.com
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now? - The Globe and Mail
Is Bristol Myers Squibb Company stock resilient to inflationPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - newser.com
Analyst Says Bristol-Myers Squibb (BMY) Among the Best ‘Deep Value’ Stocks to Buy - Yahoo Finance
Risk adjusted return profile for Bristol Myers Squibb Company Equity Right analyzedPortfolio Profit Report & AI Enhanced Trading Alerts - newser.com
Forecasting Bristol Myers Squibb Company Equity Right price range with options dataMarket Volume Summary & Fast Exit/Entry Strategy Plans - newser.com
Will Bristol Myers Squibb Company stock deliver better than expected guidanceTrade Risk Summary & Low Drawdown Trading Strategies - newser.com
Can Bristol-Myers Squibb’s Innovation Push Reverse Its Stock Slide? - AD HOC NEWS
Is Bristol Myers Squibb Company (BRM) stock cheap vs fundamentalsJuly 2025 Selloffs & AI Forecast for Swing Trade Picks - newser.com
Bristol-Myers $450M Payment Dispute Heads To Arbitration - Law360
Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks - The Motley Fool
Bristol Myers Squibb (BMY) Stock Moves 2.18%: What You Should Know - Yahoo Finance
Trend analysis for Bristol Myers Squibb Company this week2025 Technical Overview & Stepwise Trade Signal Implementation - newser.com
The Play On Bristol-Myers Squibb (NYSE:BMY) - Seeking Alpha
Citi Raises PT on Bristol-Myers Squibb Company (BMY) Stock - Insider Monkey
Small Cell Lung Cancer Market Research 2025-2035: Growth Driven by Advancements in Novel Therapies, Including Immunotherapies, Targeted Therapies, and Combination Treatments - GlobeNewswire Inc.
How high can Bristol Myers Squibb Company stock goJuly 2025 News Drivers & AI Powered Buy and Sell Recommendations - newser.com
Will Bristol Myers Squibb Company Celegne Contingent stock benefit from Fed rate cuts2025 Technical Overview & High Accuracy Swing Entry Alerts - newser.com
Bristol-Myers’ $450 Million Earnout Pay Fight Sent to Arbitrator - Bloomberg Law News
US CBO says orphan drug exemption could add $6 billion to cost of Trump's 'Big Beautiful Bill' - Reuters
Can Bristol-Myers Squibb Stock Recover After Steep Decline? - AD HOC NEWS
Bristol-Myers Squibb (BMY) Investor Outlook: Navigating a 21.59% Potential Upside Amidst Strong Dividend Yield - DirectorsTalk Interviews
Can Bristol Myers Squibb Company stock hit record highs againMarket Performance Recap & Expert Verified Movement Alerts - newser.com
Bristol Myers (BMY) Reports Positive Trial Data on Cancer Drug - GuruFocus
Bristol Myers Squibb (BMY) Reports Promising Phase I Trial Resul - GuruFocus
Bristol Myers Squibb, SystImmune report data from lung cancer trial - Seeking Alpha
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025 - Yahoo Finance
Bristol Myers Squibb Foundation Awards Grant to PATH to Improve Care for Inherited Blood Disorders in India - Yahoo Finance
Is Bristol Myers Squibb Company Equity Right building a consolidation baseMarket Trend Review & Step-by-Step Trade Execution Guides - newser.com
Does Bristol Myers Stock Offer Value as AI Data-Sharing Alliance Makes Headlines? - simplywall.st
insitro and Bristol Myers Squibb (BMY) Advance ALS Research with New AI-Powered Collaboration - Yahoo Finance
Bristol Myers Squibb Launches Kopozgo (Mavacamten) In IndiaStatement - TradingView
What machine learning models say about Bristol Myers Squibb CompanyWatch List & Fast Moving Stock Trade Plans - newser.com
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Orbital Therapeutics Deal - Insider Monkey
insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform - BioSpace
insitro, Bristol Myers Squibb extend ALS collaboration with AI focus - Investing.com
insitro, Bristol Myers Squibb extend ALS collaboration with AI focus By Investing.com - Investing.com Australia
BMY Collaboration Advances ALS Treatment Development - GuruFocus
$20M Added to insitro–Bristol Myers Squibb ALS Collaboration; Novel ALS Target Identified - Stock Titan
Bristol Myers Squibb describes new FAK degradation inducers - BioWorld MedTech
11 Years of Global Patient Week: Bristol Myers Squibb Brings Joy to Patients with Toy-Making Workshops Across the Region - PR Newswire UK
Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn - European Pharmaceutical Review
What Bristol-Myers Squibb (BMY)'s FDA Fast Track for Alzheimer’s Drug Means for Shareholders - simplywall.st
Bristol Myers' $1.5 Billion RNA Gamble: Could Orbital Therapeutics Rewire Its Future? - Smartkarma
What to Expect From Bristol-Myers Squibb's Next Quarterly Earnings Report - inkl
Analyzing net buyer seller activity in Bristol Myers Squibb Company Equity RightWeekly Investment Recap & Smart Investment Allocation Tips - newser.com
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.28%
0.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):